Risk of subclinical atherosclerosis across metabolic transition in individuals with or without fatty liver disease: a prospective cohort study

Table 2 Risk of incident subclinical atherosclerosis (composite/separate) according to MH/MU and fatty liver status at baseline

	N	Case, n (%)	Model 1 OR (95% CI)	P value	Model 2 OR (95% CI)	P value
Composite Subclinical atherosclerosis (902/3734, 24.2%)
MHNHS	1092	152 (13.9)	1.00	–	1.00	–
MUNHS	1617	439 (27.2)	1.95 (1.58–2.41)	< 0.0001	1.66 (1.30–2.13)	< 0.0001
MHHS	54	10 (18.5)	1.57 (0.76–3.25)	0.2267	1.56 (0.68–3.56)	0.2907
MUHS	971	301 (31.0)	2.60 (2.07–3.27)	< 0.0001	2.57 (1.90–3.48)	< 0.0001
Elevated baPWV (827/4667, 17.7%)
MHNHS	1231	118 (9.6)	1.00	–	1.00	–
MUNHS	2107	430 (20.4)	1.88 (1.50–2.37)	< 0.0001	1.82 (1.38–2.40)	< 0.0001
MHHS	57	6 (10.5)	1.29 (0.53–3.17)	0.5734	1.69 (0.62–4.57)	0.3043
MUHS	1272	273 (21.5)	2.34 (1.83–2.99)	< 0.0001	2.48 (1.78–3.45)	< 0.0001
Elevated PP (627/4668, 13.4%)
MHNHS	1247	71 (5.7)	1.00	–	1.00	–
MUNHS	2078	338 (16.3)	2.55 (1.94–3.35)	< 0.0001	2.42 (1.75–3.36)	< 0.0001
MHHS	58	4 (6.9)	1.49 (0.52–4.31)	0.4594	2.08 (0.70–6.20)	0.1890
MUHS	1285	214 (16.7)	2.83 (2.12–3.77)	< 0.0001	2.92 (2.00–4.26)	< 0.0001
Albuminuria (476/5753, 8.3%)
MHNHS	1302	70 (5.4)	1.00	–	1.00	–
MUNHS	2684	211 (7.9)	1.18 (0.88–1.57)	0.2684	1.09 (0.77–1.53)	0.6276
MHHS	63	3 (4.8)	1.00 (0.30–3.28)	0.9939	0.85 (0.20–3.63)	0.8233
MUHS	1704	192 (11.3)	2.01 (1.50–2.69)	< 0.0001	1.81 (1.23–2.65)	0.0024

Model 1 was adjusted for age, sex and follow-up interval;
Model 2 was further adjusted for current smoking and drinking status (yes/no), education (≥ 12 years or not), log-transformed physical activity, baseline BMI and BMI change
MHNHS metabolic healthy and no hepatic steatosis; MUNHS metabolic unhealthy and no hepatic steatosis; MHHS metabolic healthy and hepatic steatosis; MUHS metabolic unhealthy and hepatic steatosis; baPWV brachial–ankle pulse wave velocity; PP pulse pressure; OR odds ratio; BMI body mass index

ISSN: 1743-7075